Overweight Clinical Trial
Official title:
The Efficacy of Chlorella Supplementation on Health and Performance Following a 12-week Training Programme
Verified date | January 2024 |
Source | University College, London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Algae are an emerging functional food source that are gaining traction and popularity in biopharmaceutical, nutraceutical, and biotechnology industries. They are a diverse and complex species that comprise an abundant breadth of micronutrients (multiple vitamins, minerals, fatty acids, and amino acids) that can possibly promote human health. One such popular algae is chlorella, a unicellular dark green organism, which can be readily bought in health stores worldwide. Although there is some promising data to suggest chlorella supplementation can alleviate cardiovascular risk factors and improve VO2max from supplementation alone, an area which has particularly limited existing literature is the possible ergogenic and health influence of chlorella supplementation combined with a controlled training programme in sedentary and overweight populations. Given that such populations are susceptible to increased risk of developing associated diseases (cardiovascular disease, diabetes, hypertension) and possess poor diets, there is a need to investigate the possible synergistic effect of a training programme and supplementation of algae further. Furthermore, there is growing evidence to suggest that supplementation with algae may have a beneficial effect on cognitive function, primarily owed to antioxidant and anti-inflammatory mechanisms. Therefore, the purpose of this study aims to assess the efficacy of chlorella supplementation on VO2max, blood lipid profiles, cognitive function and body composition following a 12-week training programme. Briefly, in a double blind, randomised, placebo-controlled trial, participants will be randomly allocated into 1 of 4 groups (A. Exercise + Chlorella, B. Exercise + Placebo, C. Control + Chlorella, D. Control + Placebo).
Status | Completed |
Enrollment | 36 |
Est. completion date | September 23, 2023 |
Est. primary completion date | August 1, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - Aged 18-50 - Classified a sedentary (<30 minutes of moderate intensity exercise for <3 days per week for 3 months) and/or overweight (BMI = 25 +) - Be willing to complete a 12-week training programme Exclusion Criteria: - Individuals taking blood thinners. - Known allergies to algae/mould and iodine. - Taking immunosuppressant medication - Regularly ingesting algae - Smokers |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University Colllege London (ISEH) | London |
Lead Sponsor | Collaborator |
---|---|
University College, London |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in cardiovascular fitness (VO2max) | Changes in cardiovascular fitness variables as measured by a Cardio Pulmonary Exercise Test. | At baseline, week 6 and at week 12 | |
Primary | Changes in blood lipid profiling | Assessing changes in blood lipids (Triglycerides, cholesterol, low-density lipoprotein, High-density lipoprotein) | At baseline, week 6 and at week 12 | |
Secondary | Changes in cognitive function (simple reaction time) | Assessing changes in simple reaction time (m/s & number of errors) using the Gorilla Experiment Builder on a laptop. | At baseline, week 6 and at week 12 (before and after exercise) | |
Secondary | Changes in cognitive function (inhibition) | Assessing changes in inhibition (m/s & number of errors) using the Gorilla Experiment Builder on a laptop. | At baseline, week 6 and at week 12 (before and after exercise) | |
Secondary | Changes in cognitive function (endogenous and exogenous attending) | Assessing changes in endogenous and exogenous attending (m/s & number of errors) using the Gorilla Experiment Builder on a laptop. | At baseline, week 6 and at week 12 (before and after exercise) | |
Secondary | Changes in cognitive function (context memory) | Assessing changes in source and context memory (m/s & number of errors) using the Gorilla Experiment Builder on a laptop. spatial anticipation | At baseline, week 6 and at week 12 (before and after exercise) | |
Secondary | Changes in cognitive function (spatial anticipation) | Assessing changes in spatial anticipation (m/s & number of errors) using the Gorilla Experiment Builder on a laptop. | At baseline, week 6 and at week 12 (before and after exercise) | |
Secondary | Changes in body composition variables | Assessing changes in body composition variables using the Tanita. Weight (kg) and height (cm) will be combined to report BMI in kg/m^2. | At baseline, week 6 and at week 12 | |
Secondary | Changes in body composition variables (fat & lean mass percentage) | Assessing changes in body fat mass (Body Fat mass %) and lean mass in percentage (Lean mass %) using the Tanita. | At baseline, week 6 and at week 12 | |
Secondary | Changes in body composition variables (fat free and muscle mass) | Assessing changes in fat free mass (kg) and muscle mass (kg) using the Tanita. | At baseline, week 6 and at week 12 | |
Secondary | Changes in blood pressure | Assessing changes in blood pressure (mmHg). Systolic and diastolic, using the ABP-Monitor Mobil-O-Graph NG | At baseline, week 6 and at week 12 | |
Secondary | Changes in pulse wave velocity | Assessing changes in pulse wave velocity (PWV) using the ABP-Monitor Mobil-O-Graph NG. | At baseline, week 6 and at week 12 | |
Secondary | Changes in total vascular resistance | Assessing changes in total vascular resistance (TVR) using the ABP-Monitor Mobil-O-Graph NG. | At baseline, week 6 and at week 12 | |
Secondary | Changes in augmentation index | Assessing changes in augmentation index (Alx) using the ABP-Monitor Mobil-O-Graph NG. | At baseline, week 6 and at week 12 | |
Secondary | Changes in augmentation pressure | Assessing changes in augmentation pressure using the ABP-Monitor Mobil-O-Graph NG. | At baseline, week 6 and at week 12 | |
Secondary | Changes in lactate | Assessing changes in lactate at rest, peak, +5mins post, +10mins post, +30mins post | At baseline, week 6 and at week 12 | |
Secondary | Changes in biomarkers for brain health | Assessing changes in Brain-Derived Neurotrophic Factor (before exercise at rest and 30-mins post peak exercise) | At baseline, week 6 and at week 12 | |
Secondary | Changes in Nitrate/Nitrite | Assessing changes in plasma Nitrate and Nitrite concentrations | At baseline, week 6 and at week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Terminated |
NCT03299881 -
Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss
|
N/A | |
Completed |
NCT02805478 -
Fat-Associated Cardiovascular Organ Dysfunction
|
||
Active, not recruiting |
NCT02558920 -
Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
|
||
Completed |
NCT03759743 -
Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject
|
N/A | |
Completed |
NCT03610958 -
Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.
|
N/A | |
Completed |
NCT03678766 -
CHARGE: Controlling Hunger and ReGulating Eating
|
N/A | |
Completed |
NCT04430465 -
Effects of Wholegrains on Children's Health (KORN)
|
N/A | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT05376865 -
Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers
|
N/A | |
Completed |
NCT03625427 -
Effect of Palmitoleic Acid on C-reactive Protein
|
N/A | |
Active, not recruiting |
NCT03435445 -
Online Platform for Healthy Weight Loss (POEmaS)
|
N/A | |
Enrolling by invitation |
NCT05576116 -
Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics
|
N/A | |
Recruiting |
NCT05249465 -
Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention
|
N/A | |
Active, not recruiting |
NCT06023095 -
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
|
Phase 1 | |
Completed |
NCT03648892 -
Brain Dopamine Function in Human Obesity
|
Early Phase 1 | |
Not yet recruiting |
NCT05751993 -
Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions
|
N/A | |
Recruiting |
NCT02887950 -
Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause
|
N/A | |
Completed |
NCT03097237 -
High Fiber Rye Foods for Weight and Body Fat Reduction
|
N/A | |
Completed |
NCT02829229 -
Community-based Obesity Treatment in African American Women After Childbirth
|
N/A |